CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpilefunding and preparation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Education EDU
Support HR 5116, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Medical/Disease Research/Clinical Labs MED
Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education and strategic stockpilefunding and preparation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Science/Technology SCI
Support HR 5116, America COMPETES Act Reauthorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Health Issues HCR
Address implementation of comparative effectiveness research provision of healthcare reform law. Address implementation/impact of Therapeutic Discovery Tax Credit provision of healthcare reform law. Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl 510(k) process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Financial Institutions/Investments/Securities FIN
Support permanent exemption from Section 404(b) reporting requirements of the Sarbanes-Oxley Act for smaller issuers in financial services reform bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Taxation/Internal Revenue Code TAX
Address implementation/impact of Therapeutic Discovery Tax Credit provision of healthcare reform law.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Medicare/Medicaid MMM
Address implementation of comparative effectiveness research provision of healthcare reform law.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD E GILLENWATER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.